- Home
- ANTX vs ENLV Comparison
ANTX vs ENLV Comparison
Compare ANTX & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANTX | ENLV |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.7M | 149.0M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ANTX | ENLV |
|---|---|---|
| Price | $4.45 | $0.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 383.9K | 343.3K |
| Earning Date | 05-13-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.52 |
| 52 Week High | $6.91 | $2.10 |
Technical Indicators
Market Signals| Indicator | ANTX | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 26.36 |
| Support Level | $3.82 | N/A |
| Resistance Level | $5.21 | $1.25 |
| Average True Range (ATR) | 0.40 | 0.05 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 0.91 | 3.53 |
Price Performance
Historical ComparisonAbout ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.